XML 79 R56.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments of business and geographic areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025 | Sep. 29, 2024
Sales by segment of business |  |  |  |
Sales to customers | $ 23,993 | $ 22,471 | $ 69,629 | $ 66,301
Percent Change (as a percent) | 6.80% |  | 5.00% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,708 | 12,909 | $ 39,557 | 37,098
Percent Change (as a percent) | 6.20% |  | 6.60% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,285 | 9,562 | $ 30,072 | 29,203
Percent Change (as a percent) | 7.60% |  | 3.00% |
Innovative Medicine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 15,563 | 14,580 | $ 44,638 | 42,632
Percent Change (as a percent) | 6.80% |  | 4.70% |
Innovative Medicine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,402 | 8,871 | $ 26,655 | 24,993
Percent Change (as a percent) | 6.00% |  | 6.70% |
Innovative Medicine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,161 | 5,709 | $ 17,983 | 17,639
Percent Change (as a percent) | 7.90% |  | 1.90% |
Innovative Medicine | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,529 | 5,380 | $ 18,519 | 15,284
Percent Change (as a percent) | 21.30% |  | 21.20% |
Innovative Medicine | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,468 | 2,816 | $ 9,866 | 7,835
Percent Change (as a percent) | 23.20% |  | 25.90% |
Innovative Medicine | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,060 | 2,565 | $ 8,652 | 7,450
Percent Change (as a percent) | 19.30% |  | 16.10% |
Innovative Medicine | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 524 | 286 | $ 1,332 | 629
Percent Change (as a percent) | 83.50% |  |  |
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 396 | 258 | $ 1,072 | 565
Percent Change (as a percent) | 53.30% |  | 89.60% |
Innovative Medicine | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 128 | 27 | $ 260 | 63
Innovative Medicine | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,672 | 3,016 | $ 10,448 | 8,586
Percent Change (as a percent) | 21.70% |  | 21.70% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,088 | 1,684 | $ 5,934 | 4,789
Percent Change (as a percent) | 24.00% |  | 23.90% |
Innovative Medicine | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,584 | 1,332 | $ 4,514 | 3,797
Percent Change (as a percent) | 18.90% |  | 18.90% |
Innovative Medicine | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 936 | 790 | $ 2,615 | 2,215
Percent Change (as a percent) | 18.40% |  | 18.00% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 378 | 337 | $ 1,048 | 940
Percent Change (as a percent) | 12.30% |  | 11.50% |
Innovative Medicine | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 558 | 453 | $ 1,567 | 1,275
Percent Change (as a percent) | 23.00% |  | 22.90% |
Innovative Medicine | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 695 | 753 | $ 2,139 | 2,307
Percent Change (as a percent) | (7.80%) |  | (7.30%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 211 | 259 | $ 685 | 770
Percent Change (as a percent) | (18.30%) |  | (11.00%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 483 | 494 | $ 1,453 | 1,537
Percent Change (as a percent) | (2.30%) |  | (5.40%) |
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 198 | 89 | $ 518 | 205
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 136 | 68 | 388 | 156
Percent Change (as a percent) | 99.70% |  |  |
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 21 | 130 | 49
Innovative Medicine | Oncology | TALVEY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 122 | 75 | $ 314 | 202
Percent Change (as a percent) | 60.80% |  | 55.30% |
Innovative Medicine | Oncology | TALVEY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 85 | 64 | $ 235 | 173
Percent Change (as a percent) | 34.20% |  | 35.80% |
Innovative Medicine | Oncology | TALVEY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 37 | 12 | $ 79 | 29
Innovative Medicine | Oncology | Tecvayli |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 177 | 135 | $ 494 | 403
Percent Change (as a percent) | 31.30% |  | 22.60% |
Innovative Medicine | Oncology | Tecvayli | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 115 | 105 | $ 334 | 310
Percent Change (as a percent) | 9.30% |  | 7.50% |
Innovative Medicine | Oncology | Tecvayli | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 62 | 30 | $ 160 | 93
Percent Change (as a percent) |  |  | 73.00% |
Innovative Medicine | Oncology | ZYTIGA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 113 | 150 | $ 383 | 496
Percent Change (as a percent) | (25.10%) |  | (22.80%) |
Innovative Medicine | Oncology | ZYTIGA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5 | 5 | $ 18 | 25
Percent Change (as a percent) | (25.00%) |  | (30.40%) |
Innovative Medicine | Oncology | ZYTIGA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 108 | 144 | $ 365 | 470
Percent Change (as a percent) | (25.10%) |  | (22.30%) |
Innovative Medicine | Oncology | Other Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 86 | $ 276 | 242
Percent Change (as a percent) | 9.70% |  | 14.00% |
Innovative Medicine | Oncology | Other Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 56 | 36 | $ 153 | 106
Percent Change (as a percent) | 54.60% |  | 44.80% |
Innovative Medicine | Oncology | Other Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 39 | 50 | $ 123 | 136
Percent Change (as a percent) | (22.20%) |  | (9.70%) |
Innovative Medicine | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,168 | 4,621 | $ 11,868 | 13,590
Percent Change (as a percent) | (9.80%) |  | (12.70%) |
Innovative Medicine | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,676 | 3,068 | $ 7,377 | 8,499
Percent Change (as a percent) | (12.80%) |  | (13.20%) |
Innovative Medicine | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,493 | 1,552 | $ 4,492 | 5,090
Percent Change (as a percent) | (3.90%) |  | (11.80%) |
Innovative Medicine | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 476 | 419 | $ 1,398 | 1,246
Percent Change (as a percent) | 13.60% |  | 12.20% |
Innovative Medicine | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 326 | 281 | $ 923 | 778
Percent Change (as a percent) | 16.20% |  | 18.70% |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 19 | 27 | $ 63 | 89
Percent Change (as a percent) | (30.90%) |  | (29.60%) |
Innovative Medicine | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 132 | 112 | $ 413 | 380
Percent Change (as a percent) | 17.70% |  | 8.60% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 687 | 516 | $ 2,036 | 1,607
Percent Change (as a percent) | 32.90% |  | 26.70% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 309 | 299 | $ 906 | 820
Percent Change (as a percent) | 3.60% |  | 10.50% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 377 | 218 | $ 1,130 | 787
Percent Change (as a percent) | 73.00% |  | 43.50% |
Innovative Medicine | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,570 | 2,676 | $ 4,848 | 8,012
Percent Change (as a percent) | (41.30%) |  | (39.50%) |
Innovative Medicine | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,022 | 1,770 | $ 3,081 | 5,021
Percent Change (as a percent) | (42.30%) |  | (38.60%) |
Innovative Medicine | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 549 | 906 | $ 1,768 | 2,991
Percent Change (as a percent) | (39.40%) |  | (40.90%) |
Innovative Medicine | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,424 | 1,007 | $ 3,566 | 2,721
Percent Change (as a percent) | 41.30% |  | 31.00% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 989 | 691 | $ 2,384 | 1,789
Percent Change (as a percent) | 43.10% |  | 33.30% |
Innovative Medicine | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 434 | 316 | $ 1,181 | 932
Percent Change (as a percent) | 37.40% |  | 26.70% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12 | 1 | $ 21 | 3
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 12 | 1 | 21 | 3
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 829 | 836 | $ 2,434 | 2,622
Percent Change (as a percent) | (0.90%) |  | (7.20%) |
Innovative Medicine | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 326 | 365 | $ 961 | 1,023
Percent Change (as a percent) | (10.50%) |  | (6.00%) |
Innovative Medicine | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 501 | 471 | $ 1,472 | 1,599
Percent Change (as a percent) | 6.40% |  | (7.90%) |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 385 | 330 | $ 1,103 | 950
Percent Change (as a percent) | 16.40% |  | 16.10% |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7 | 8 | $ 21 | 24
Percent Change (as a percent) | (7.90%) |  | (11.80%) |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 378 | 323 | $ 1,082 | 926
Percent Change (as a percent) | 16.90% |  | 16.80% |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 397 | 449 | $ 1,196 | 1,305
Percent Change (as a percent) | (11.60%) |  | (8.30%) |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 315 | 355 | $ 932 | 990
Percent Change (as a percent) | (11.00%) |  | (5.80%) |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 81 | 94 | $ 264 | 315
Percent Change (as a percent) | (13.60%) |  | (16.10%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 56 | $ 135 | 367
Percent Change (as a percent) | (17.50%) |  | (63.30%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4 | 3 | $ 8 | 10
Percent Change (as a percent) | 57.30% |  | (11.00%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 42 | 54 | $ 126 | 358
Percent Change (as a percent) | (21.20%) |  | (64.70%) |
Innovative Medicine | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,024 | 1,755 | $ 5,722 | 5,340
Percent Change (as a percent) | 15.30% |  | 7.20% |
Innovative Medicine | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,367 | 1,094 | $ 3,712 | 3,250
Percent Change (as a percent) | 25.00% |  | 14.20% |
Innovative Medicine | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 658 | 662 | $ 2,011 | 2,090
Percent Change (as a percent) | (0.70%) |  | (3.80%) |
Innovative Medicine | Neuroscience | CAPLYTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 240 | 0 | $ 451 | 0
Innovative Medicine | Neuroscience | CAPLYTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 240 | 0 | 451 | 0
Innovative Medicine | Neuroscience | CAPLYTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 140 | 142 | $ 452 | 482
Percent Change (as a percent) | (1.40%) |  | (6.30%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 14 | 26 | $ 76 | 101
Percent Change (as a percent) | (49.20%) |  | (24.90%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 127 | 117 | $ 376 | 382
Percent Change (as a percent) | 9.00% |  | (1.40%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 929 | 1,049 | $ 2,824 | 3,159
Percent Change (as a percent) | (11.30%) |  | (10.60%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 664 | 780 | $ 2,021 | 2,329
Percent Change (as a percent) | (14.90%) |  | (13.20%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 267 | 269 | $ 804 | 830
Percent Change (as a percent) | (0.90%) |  | (3.10%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 459 | 284 | $ 1,193 | 780
Percent Change (as a percent) | 61.50% |  | 53.00% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 405 | 243 | $ 1,047 | 660
Percent Change (as a percent) | 67.10% |  | 58.70% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 53 | 42 | $ 146 | 120
Percent Change (as a percent) | 28.90% |  | 21.90% |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 256 | 281 | $ 803 | 920
Percent Change (as a percent) | (8.90%) |  | (12.70%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 46 | 46 | $ 119 | 161
Percent Change (as a percent) | 0.40% |  | (26.40%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 210 | 235 | $ 684 | 759
Percent Change (as a percent) | (10.70%) |  | (9.80%) |
Innovative Medicine | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,115 | 1,102 | $ 3,253 | 3,190
Percent Change (as a percent) | 1.10% |  | 2.00% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 815 | 815 | $ 2,358 | 2,324
Percent Change (as a percent) | (0.10%) |  | 1.50% |
Innovative Medicine | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 300 | 287 | $ 895 | 866
Percent Change (as a percent) | 4.80% |  | 3.40% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 578 | 583 | $ 1,682 | 1,655
Percent Change (as a percent) | (0.80%) |  | 1.70% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 417 | $ 1,175 | 1,149
Percent Change (as a percent) | (1.60%) |  | 2.30% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 168 | 166 | $ 507 | 506
Percent Change (as a percent) | 1.10% |  | 0.20% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 484 | 458 | $ 1,411 | 1,352
Percent Change (as a percent) | 5.60% |  | 4.30% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 392 | 379 | $ 1,139 | 1,120
Percent Change (as a percent) | 3.50% |  | 1.70% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 92 | 80 | $ 272 | 232
Percent Change (as a percent) | 15.20% |  | 17.00% |
Innovative Medicine | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 53 | 60 | $ 160 | 183
Percent Change (as a percent) | (13.10%) |  | (12.70%) |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13 | 21 | $ 44 | 56
Percent Change (as a percent) | (36.50%) |  | (21.50%) |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 39 | 39 | $ 116 | 127
Percent Change (as a percent) | (1.00%) |  | (8.90%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 899 | 884 | $ 2,842 | 2,605
Percent Change (as a percent) | 1.70% |  | 9.10% |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 750 | 713 | $ 2,381 | 2,061
Percent Change (as a percent) | 5.30% |  | 15.50% |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 170 | $ 461 | 543
Percent Change (as a percent) | (13.10%) |  | (15.20%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 264 | 292 | $ 896 | 908
Percent Change (as a percent) | (9.80%) |  | (1.30%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 115 | 121 | $ 435 | 364
Percent Change (as a percent) | (5.20%) |  | 19.40% |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 170 | $ 461 | 543
Percent Change (as a percent) | (13.10%) |  | (15.20%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 635 | 592 | $ 1,946 | 1,697
Percent Change (as a percent) | 7.40% |  | 14.70% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 635 | 592 | $ 1,946 | 1,697
Percent Change (as a percent) | 7.40% |  | 14.70% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,430 | 7,891 | $ 24,991 | 23,669
Percent Change (as a percent) | 6.80% |  | 5.60% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,306 | 4,038 | $ 12,902 | 12,105
Percent Change (as a percent) | 6.60% |  | 6.60% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,124 | 3,853 | $ 12,089 | 11,564
Percent Change (as a percent) | 7.00% |  | 4.50% |
MEDTECH | Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,213 | 1,966 | $ 6,629 | 5,645
Percent Change (as a percent) | 12.60% |  | 17.40% |
MEDTECH | Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,306 | 1,148 | $ 3,931 | 3,292
Percent Change (as a percent) | 13.80% |  | 19.40% |
MEDTECH | Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 908 | 819 | $ 2,698 | 2,353
Percent Change (as a percent) | 10.80% |  | 14.60% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,418 | 1,279 | $ 4,209 | 3,946
Percent Change (as a percent) | 10.80% |  | 6.70% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 720 | 660 | $ 2,145 | 2,057
Percent Change (as a percent) | 9.10% |  | 4.30% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 698 | 619 | $ 2,064 | 1,889
Percent Change (as a percent) | 12.60% |  | 9.20% |
MEDTECH | ABIOMED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 423 | 362 | $ 1,291 | 1,112
Percent Change (as a percent) | 16.80% |  | 16.10% |
MEDTECH | ABIOMED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 336 | 293 | $ 1,035 | 905
Percent Change (as a percent) | 14.50% |  | 14.30% |
MEDTECH | ABIOMED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 86 | 68 | $ 256 | 207
Percent Change (as a percent) | 26.80% |  | 23.90% |
MEDTECH | Shockwave |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 278 | 229 | $ 828 | 306
Percent Change (as a percent) | 21.20% |  |  |
MEDTECH | Shockwave | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 220 | 163 | 659 | 240
Percent Change (as a percent) | 34.40% |  |  |
MEDTECH | Shockwave | U.S. | Revision of Prior Period, Reclassification, Adjustment |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers |  | 20 |  |
MEDTECH | Shockwave | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 59 | 66 | 169 | 66
Percent Change (as a percent) | (11.20%) |  |  |
MEDTECH | Shockwave | International | Revision of Prior Period, Reclassification, Adjustment |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers |  | (20) |  |
MEDTECH | Other Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 95 | 96 | $ 302 | 281
Percent Change (as a percent) | (0.70%) |  | 7.50% |
MEDTECH | Other Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 30 | 30 | $ 93 | 89
Percent Change (as a percent) | 0.00% |  | 4.20% |
MEDTECH | Other Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 66 | $ 209 | 192
Percent Change (as a percent) | (1.00%) |  | 9.00% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,274 | 2,191 | $ 6,820 | 6,843
Percent Change (as a percent) | 3.80% |  | (0.30%) |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,396 | 1,359 | $ 4,200 | 4,229
Percent Change (as a percent) | 2.70% |  | (0.70%) |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 878 | 832 | $ 2,620 | 2,614
Percent Change (as a percent) | 5.60% |  | 0.30% |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 405 | 381 | $ 1,235 | 1,220
Percent Change (as a percent) | 6.40% |  | 1.30% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 262 | 250 | $ 796 | 785
Percent Change (as a percent) | 4.70% |  | 1.30% |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 144 | 131 | $ 440 | 435
Percent Change (as a percent) | 9.70% |  | 1.20% |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 377 | 352 | $ 1,155 | 1,147
Percent Change (as a percent) | 7.00% |  | 0.70% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 216 | 212 | $ 673 | 684
Percent Change (as a percent) | 2.10% |  | (1.50%) |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 160 | 140 | $ 482 | 463
Percent Change (as a percent) | 14.30% |  | 4.00% |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 793 | 761 | $ 2,333 | 2,285
Percent Change (as a percent) | 4.20% |  | 2.10% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 512 | 497 | $ 1,515 | 1,499
Percent Change (as a percent) | 3.00% |  | 1.10% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 265 | $ 818 | 786
Percent Change (as a percent) | 6.40% |  | 4.10% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 698 | 696 | $ 2,096 | 2,191
Percent Change (as a percent) | 0.30% |  | (4.30%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 406 | 400 | $ 1,216 | 1,262
Percent Change (as a percent) | 1.30% |  | (3.70%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 293 | 296 | $ 881 | 930
Percent Change (as a percent) | (1.10%) |  | (5.30%) |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,542 | 2,434 | $ 7,493 | 7,338
Percent Change (as a percent) | 4.40% |  | 2.10% |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,031 | 983 | $ 3,076 | 2,965
Percent Change (as a percent) | 4.90% |  | 3.80% |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,511 | 1,451 | $ 4,417 | 4,373
Percent Change (as a percent) | 4.10% |  | 1.00% |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,165 | 1,109 | $ 3,402 | 3,337
Percent Change (as a percent) | 5.00% |  | 1.90% |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 477 | 448 | $ 1,411 | 1,360
Percent Change (as a percent) | 6.20% |  | 3.70% |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 688 | 661 | $ 1,991 | 1,977
Percent Change (as a percent) | 4.20% |  | 0.70% |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,378 | 1,325 | $ 4,092 | 4,001
Percent Change (as a percent) | 3.90% |  | 2.30% |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 555 | 535 | $ 1,666 | 1,605
Percent Change (as a percent) | 3.80% |  | 3.80% |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 823 | 791 | $ 2,426 | 2,397
Percent Change (as a percent) | 4.00% |  | 1.20% |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,400 | 1,300 | $ 4,048 | 3,843
Percent Change (as a percent) | 7.70% |  | 5.30% |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 571 | 549 | $ 1,694 | 1,619
Percent Change (as a percent) | 4.20% |  | 4.70% |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 828 | 751 | $ 2,354 | 2,224
Percent Change (as a percent) | 10.20% |  | 5.80% |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,018 | 968 | $ 2,902 | 2,796
Percent Change (as a percent) | 5.20% |  | 3.80% |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 456 | 441 | $ 1,337 | 1,288
Percent Change (as a percent) | 3.50% |  | 3.80% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 562 | 527 | $ 1,565 | 1,508
Percent Change (as a percent) | 6.60% |  | 3.80% |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 383 | 333 | $ 1,147 | 1,048
Percent Change (as a percent) | 14.90% |  | 9.40% |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 116 | 108 | $ 358 | 331
Percent Change (as a percent) | 7.00% |  | 8.00% |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 266 | $ 225 | $ 789 | $ 717
Percent Change (as a percent) | 18.70% |  | 10.10% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RYBREVANTLAZCLUZEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TALVEYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TecvayliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CAPLYTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITOPSYNVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ShockwaveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |